Comprehensive Pharmacogenomic Profiling of Malignant Pleural Mesothelioma Identifies a Subgroup Sensitive to FGFR Inhibition
Despite intense research, treatment options for patients with mesothelioma are limited and offer only modest survival advantage. We screened a large panel of compounds in multiple mesothelioma models and correlated sensitivity with a range of molecular features to detect biomarkers of drug response....
Gespeichert in:
| Veröffentlicht in: | Clinical cancer research Jg. 24; H. 1; S. 84 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
United States
01.01.2018
|
| Schlagworte: | |
| ISSN: | 1557-3265, 1557-3265 |
| Online-Zugang: | Weitere Angaben |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | Despite intense research, treatment options for patients with mesothelioma are limited and offer only modest survival advantage. We screened a large panel of compounds in multiple mesothelioma models and correlated sensitivity with a range of molecular features to detect biomarkers of drug response.
We utilized a high-throughput chemical inhibitor screen in a panel of 889 cancer cell lines, including both immortalized and primary early-passage mesothelioma lines, alongside comprehensive molecular characterization using Illumina whole-exome sequencing, copy-number analysis and Affymetrix array whole transcriptome profiling. Subsequent validation was done using functional assays such as siRNA silencing and mesothelioma mouse xenograft models.
A subgroup of immortalized and primary MPM lines appeared highly sensitive to FGFR inhibition. None of these lines harbored genomic alterations of FGFR family members, but rather BAP1 protein loss was associated with enhanced sensitivity to FGFR inhibition. This was confirmed in an MPM mouse xenograft model and by BAP1 knockdown and overexpression in cell line models. Gene expression analyses revealed an association between BAP1 loss and increased expression of the receptors FGFR1/3 and ligands FGF9/18. BAP1 loss was associated with activation of MAPK signaling. These associations were confirmed in a cohort of MPM patient samples.
A subgroup of mesotheliomas cell lines harbor sensitivity to FGFR inhibition. BAP1 protein loss enriches for this subgroup and could serve as a potential biomarker to select patients for FGFR inhibitor treatment. These data identify a clinically relevant MPM subgroup for consideration of FGFR therapeutics in future clinical studies.
. |
|---|---|
| AbstractList | Purpose: Despite intense research, treatment options for patients with mesothelioma are limited and offer only modest survival advantage. We screened a large panel of compounds in multiple mesothelioma models and correlated sensitivity with a range of molecular features to detect biomarkers of drug response.Experimental design: We utilized a high-throughput chemical inhibitor screen in a panel of 889 cancer cell lines, including both immortalized and primary early-passage mesothelioma lines, alongside comprehensive molecular characterization using Illumina whole-exome sequencing, copy-number analysis and Affymetrix array whole transcriptome profiling. Subsequent validation was done using functional assays such as siRNA silencing and mesothelioma mouse xenograft models.Results: A subgroup of immortalized and primary MPM lines appeared highly sensitive to FGFR inhibition. None of these lines harbored genomic alterations of FGFR family members, but rather BAP1 protein loss was associated with enhanced sensitivity to FGFR inhibition. This was confirmed in an MPM mouse xenograft model and by BAP1 knockdown and overexpression in cell line models. Gene expression analyses revealed an association between BAP1 loss and increased expression of the receptors FGFR1/3 and ligands FGF9/18. BAP1 loss was associated with activation of MAPK signaling. These associations were confirmed in a cohort of MPM patient samples.Conclusions: A subgroup of mesotheliomas cell lines harbor sensitivity to FGFR inhibition. BAP1 protein loss enriches for this subgroup and could serve as a potential biomarker to select patients for FGFR inhibitor treatment. These data identify a clinically relevant MPM subgroup for consideration of FGFR therapeutics in future clinical studies. Clin Cancer Res; 24(1); 84-94. ©2017 AACR.Purpose: Despite intense research, treatment options for patients with mesothelioma are limited and offer only modest survival advantage. We screened a large panel of compounds in multiple mesothelioma models and correlated sensitivity with a range of molecular features to detect biomarkers of drug response.Experimental design: We utilized a high-throughput chemical inhibitor screen in a panel of 889 cancer cell lines, including both immortalized and primary early-passage mesothelioma lines, alongside comprehensive molecular characterization using Illumina whole-exome sequencing, copy-number analysis and Affymetrix array whole transcriptome profiling. Subsequent validation was done using functional assays such as siRNA silencing and mesothelioma mouse xenograft models.Results: A subgroup of immortalized and primary MPM lines appeared highly sensitive to FGFR inhibition. None of these lines harbored genomic alterations of FGFR family members, but rather BAP1 protein loss was associated with enhanced sensitivity to FGFR inhibition. This was confirmed in an MPM mouse xenograft model and by BAP1 knockdown and overexpression in cell line models. Gene expression analyses revealed an association between BAP1 loss and increased expression of the receptors FGFR1/3 and ligands FGF9/18. BAP1 loss was associated with activation of MAPK signaling. These associations were confirmed in a cohort of MPM patient samples.Conclusions: A subgroup of mesotheliomas cell lines harbor sensitivity to FGFR inhibition. BAP1 protein loss enriches for this subgroup and could serve as a potential biomarker to select patients for FGFR inhibitor treatment. These data identify a clinically relevant MPM subgroup for consideration of FGFR therapeutics in future clinical studies. Clin Cancer Res; 24(1); 84-94. ©2017 AACR. Despite intense research, treatment options for patients with mesothelioma are limited and offer only modest survival advantage. We screened a large panel of compounds in multiple mesothelioma models and correlated sensitivity with a range of molecular features to detect biomarkers of drug response. We utilized a high-throughput chemical inhibitor screen in a panel of 889 cancer cell lines, including both immortalized and primary early-passage mesothelioma lines, alongside comprehensive molecular characterization using Illumina whole-exome sequencing, copy-number analysis and Affymetrix array whole transcriptome profiling. Subsequent validation was done using functional assays such as siRNA silencing and mesothelioma mouse xenograft models. A subgroup of immortalized and primary MPM lines appeared highly sensitive to FGFR inhibition. None of these lines harbored genomic alterations of FGFR family members, but rather BAP1 protein loss was associated with enhanced sensitivity to FGFR inhibition. This was confirmed in an MPM mouse xenograft model and by BAP1 knockdown and overexpression in cell line models. Gene expression analyses revealed an association between BAP1 loss and increased expression of the receptors FGFR1/3 and ligands FGF9/18. BAP1 loss was associated with activation of MAPK signaling. These associations were confirmed in a cohort of MPM patient samples. A subgroup of mesotheliomas cell lines harbor sensitivity to FGFR inhibition. BAP1 protein loss enriches for this subgroup and could serve as a potential biomarker to select patients for FGFR inhibitor treatment. These data identify a clinically relevant MPM subgroup for consideration of FGFR therapeutics in future clinical studies. . |
| Author | Berns, Anton Neefjes, Jacques Alifrangis, Constantine Quispel-Janssen, Josine M Brammeld, Jonathan Garnett, Matthew Iorio, Francesco Kolluri, Krishna Badhai, Jitendra Baas, Paul McDermott, Ultan Schunselaar, Laurel Price, Stacey |
| Author_xml | – sequence: 1 givenname: Josine M surname: Quispel-Janssen fullname: Quispel-Janssen, Josine M email: Constantine.alifrangis@UCLH.nhs.uk, jm.janssen@nki.nl organization: Netherlands Cancer Institute, Amsterdam, the Netherlands. Constantine.alifrangis@UCLH.nhs.uk jm.janssen@nki.nl – sequence: 2 givenname: Jitendra surname: Badhai fullname: Badhai, Jitendra organization: Netherlands Cancer Institute, Amsterdam, the Netherlands – sequence: 3 givenname: Laurel surname: Schunselaar fullname: Schunselaar, Laurel organization: Netherlands Cancer Institute, Amsterdam, the Netherlands – sequence: 4 givenname: Stacey surname: Price fullname: Price, Stacey organization: Wellcome Trust Sanger Institute, Hinxton, UK – sequence: 5 givenname: Jonathan surname: Brammeld fullname: Brammeld, Jonathan organization: Wellcome Trust Sanger Institute, Hinxton, UK – sequence: 6 givenname: Francesco surname: Iorio fullname: Iorio, Francesco organization: European Bioinformatics Institute, Hinxton, UK – sequence: 7 givenname: Krishna surname: Kolluri fullname: Kolluri, Krishna organization: UCL Dept of Respiratory Medicine, London, UK – sequence: 8 givenname: Matthew surname: Garnett fullname: Garnett, Matthew organization: Wellcome Trust Sanger Institute, Hinxton, UK – sequence: 9 givenname: Anton surname: Berns fullname: Berns, Anton organization: Netherlands Cancer Institute, Amsterdam, the Netherlands – sequence: 10 givenname: Paul surname: Baas fullname: Baas, Paul organization: Netherlands Cancer Institute, Amsterdam, the Netherlands – sequence: 11 givenname: Ultan surname: McDermott fullname: McDermott, Ultan organization: Wellcome Trust Sanger Institute, Hinxton, UK – sequence: 12 givenname: Jacques surname: Neefjes fullname: Neefjes, Jacques organization: Netherlands Cancer Institute, Amsterdam, the Netherlands – sequence: 13 givenname: Constantine surname: Alifrangis fullname: Alifrangis, Constantine email: Constantine.alifrangis@UCLH.nhs.uk, jm.janssen@nki.nl organization: Wellcome Trust Sanger Institute, Hinxton, UK. Constantine.alifrangis@UCLH.nhs.uk jm.janssen@nki.nl |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/29061644$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNkF1LwzAYhYNM3If-BCWX3nQmadI2l1LcHGw4Nr0uafumjbTJbFpB8Me74QSvzuHw8FycKRpZZwGhW0rmlIrkgZI4CQgP2TxNdwGNA0pjdoEmVIg4CFkkRv_6GE29fyeEckr4FRozSSIacT5B36lrDx3UYL35BLytVdeqwlVgXWsKvO2cNo2xFXYab1RjKqtsj7cNDJ1q8Aa862tojGsVXpVge6MNeKzwfsirzg0HvD-Z-5O7d3ixXOzwytYmP07OXqNLrRoPN-ecobfF02v6HKxflqv0cR0UnIR9QCXwJElkzKQWike80FJpYGHByjiXBQMWccJ1CFoyDsBLkijBcpHnsWAFZzN0_-s9dO5jAN9nrfEFNI2y4AafUSkEiWJB5RG9O6ND3kKZHTrTqu4r-3uM_QD5U3Ii |
| CitedBy_id | crossref_primary_10_1038_s41416_024_02661_3 crossref_primary_10_3390_cancers17091581 crossref_primary_10_1016_j_ecoenv_2025_118357 crossref_primary_10_3390_cancers15245716 crossref_primary_10_1016_j_lfs_2020_118123 crossref_primary_10_1016_j_lungcan_2023_02_024 crossref_primary_10_1002_cbin_11187 crossref_primary_10_1111_cas_13871 crossref_primary_10_1158_1541_7786_MCR_22_0635 crossref_primary_10_1016_j_canlet_2023_216395 crossref_primary_10_1016_j_lungcan_2023_107219 crossref_primary_10_1016_j_lungcan_2019_12_018 crossref_primary_10_3389_fonc_2020_00101 crossref_primary_10_3390_ijms21176342 crossref_primary_10_1038_s41572_025_00640_3 crossref_primary_10_1007_s10637_019_00783_7 crossref_primary_10_1038_s41598_017_17977_9 crossref_primary_10_3390_cells8091091 crossref_primary_10_1016_j_jtho_2018_02_021 crossref_primary_10_1136_thoraxjnl_2020_216602 crossref_primary_10_1016_j_lungcan_2020_09_022 crossref_primary_10_1016_j_semcancer_2019_09_014 crossref_primary_10_1038_s41388_018_0669_2 crossref_primary_10_1136_jim_2017_000628 crossref_primary_10_3390_cancers14174303 crossref_primary_10_1002_1878_0261_12422 crossref_primary_10_3389_fcell_2019_00221 crossref_primary_10_1111_1759_7714_15004 |
| ContentType | Journal Article |
| Copyright | 2017 American Association for Cancer Research. |
| Copyright_xml | – notice: 2017 American Association for Cancer Research. |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1158/1078-0432.CCR-17-1172 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1557-3265 |
| ExternalDocumentID | 29061644 |
| Genre | Journal Article |
| GroupedDBID | --- 18M 29B 2FS 2WC 34G 39C 53G 5GY 5RE 5VS 6J9 ABOCM ACGFO ACIWK ACPRK ACSVP ADBBV ADCOW ADNWM AENEX AFHIN AFOSN AFRAH AFUMD ALMA_UNASSIGNED_HOLDINGS BAWUL BR6 BTFSW CGR CS3 CUY CVF DIK DU5 E3Z EBS ECM EIF EJD F5P FRP GX1 H13 IH2 KQ8 L7B LSO NPM OK1 P0W P2P QTD RCR RHF RHI RNS SJN TR2 W2D W8F WOQ YKV 7X8 AAFWJ AAJMC |
| ID | FETCH-LOGICAL-c403t-19e48889729f5a464cf9afe23c2d7b9c2e26404f3ef924ee4d08a52b5bb752c42 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 33 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000437730900010&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1557-3265 |
| IngestDate | Fri Sep 05 10:25:12 EDT 2025 Wed Feb 19 02:29:43 EST 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Language | English |
| License | 2017 American Association for Cancer Research. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c403t-19e48889729f5a464cf9afe23c2d7b9c2e26404f3ef924ee4d08a52b5bb752c42 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| PMID | 29061644 |
| PQID | 1955067519 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_1955067519 pubmed_primary_29061644 |
| PublicationCentury | 2000 |
| PublicationDate | 2018-01-01 20180101 |
| PublicationDateYYYYMMDD | 2018-01-01 |
| PublicationDate_xml | – month: 01 year: 2018 text: 2018-01-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Clinical cancer research |
| PublicationTitleAlternate | Clin Cancer Res |
| PublicationYear | 2018 |
| SSID | ssj0014104 |
| Score | 2.4098759 |
| Snippet | Despite intense research, treatment options for patients with mesothelioma are limited and offer only modest survival advantage. We screened a large panel of... Purpose: Despite intense research, treatment options for patients with mesothelioma are limited and offer only modest survival advantage. We screened a large... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 84 |
| SubjectTerms | Animals Apoptosis - drug effects Apoptosis - genetics Cell Line, Tumor Cell Proliferation Cell Survival - drug effects Cell Survival - genetics Disease Models, Animal Drug Resistance, Neoplasm Drug Screening Assays, Antitumor ErbB Receptors - antagonists & inhibitors Female Fibroblast Growth Factors - metabolism Gene Amplification Gene Expression Profiling - methods Gene Expression Regulation, Neoplastic Humans Lung Neoplasms - drug therapy Lung Neoplasms - genetics Lung Neoplasms - metabolism Lung Neoplasms - pathology Male Mesothelioma - drug therapy Mesothelioma - genetics Mesothelioma - metabolism Mesothelioma - pathology Mesothelioma, Malignant Mice Pharmacogenetics - methods Pleural Neoplasms - drug therapy Pleural Neoplasms - genetics Pleural Neoplasms - metabolism Pleural Neoplasms - pathology RNA Interference Signal Transduction Tumor Suppressor Proteins - metabolism Ubiquitin Thiolesterase - metabolism Xenograft Model Antitumor Assays |
| Title | Comprehensive Pharmacogenomic Profiling of Malignant Pleural Mesothelioma Identifies a Subgroup Sensitive to FGFR Inhibition |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/29061644 https://www.proquest.com/docview/1955067519 |
| Volume | 24 |
| WOSCitedRecordID | wos000437730900010&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1NS8MwGA7qRLz4_TG_iOA12qZJ25xEhlMPG2Uq7DaSNHGDrZ3b9OSP901a2UkQvPRSWkr65snzfj0vQlcqUYrqmBOZy4QwZhWRhuZEADmJpeB5EGs_bCLpdtN-X2R1wG1el1X-YKIH6rzULkZ-Ewrg0sBuQ3E7fSduapTLrtYjNFZRIwIq46w66S-zCCz04wPhyISNRGNed_CEPAWwcMqyLKLXrVaPAFKHoRcJ_oVl-tOmvf3f79xBWzXPxHeVYeyiFVPsoY1OnUnfR18OCGZmWNWv46xWsHaSrZORxpkf5Q3HGi4t7gBXf3MFMzgbGyfTgTtm7jq3xqNyInHV62vB5cYSAxD5RhH87N7ssBQvStx-aPfwUzEcKV8hdoBe2_cvrUdST2IgmgXRgoTCwEZPBTBxyyWLmbZCWkMjTfNECU0N8KqA2chY8OeMYXmQSk4VVyrhVDN6iNaKsjDHCIeWSbjNpNEBywWXwIe0MsAz8kBLETXR5c-6DsDSXfpCFqb8mA-WK9tER9XPGUwrSY6BE60Hx4-d_OHpU7QJrCet4ihnqGFhn5tztK4_F6P57MKbEFy7WecbX9jSKg |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Comprehensive+Pharmacogenomic+Profiling+of+Malignant+Pleural+Mesothelioma+Identifies+a+Subgroup+Sensitive+to+FGFR+Inhibition&rft.jtitle=Clinical+cancer+research&rft.au=Quispel-Janssen%2C+Josine+M&rft.au=Badhai%2C+Jitendra&rft.au=Schunselaar%2C+Laurel&rft.au=Price%2C+Stacey&rft.date=2018-01-01&rft.issn=1557-3265&rft.eissn=1557-3265&rft.volume=24&rft.issue=1&rft.spage=84&rft_id=info:doi/10.1158%2F1078-0432.CCR-17-1172&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1557-3265&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1557-3265&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1557-3265&client=summon |